Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0011854 (
type 1 diabetes
)
20,749
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The changes in plasma gastrin-releasing peptide (GRP), arginine vasopressin (AVP), neuropeptide Y (NPY), corticotropin releasing hormone (CRH), galanin, ACTH, cortisol, delta sleep-inducing peptide (DSIP), adrenaline, noradrenaline and pancreatic polypeptide (PP) were measured after 5 and 15 minutes of acute insulin-induced moderate hypoglycaemia (2.0 mmol/l) in 10 patients with
Type 1 diabetes mellitus
with no
autonomic neuropathy
and in 10 healthy subjects. Plasma catecholamine and PP levels rose in both groups in response to hypoglycemia and the secretory response of ACTH was lower in the diabetic subjects (p < 0.01). GRP concentrations increased during hypoglycaemia (p < 0.01) while a reduction in AVP occurred at the start of hypoglycaemia (p < 0.001). The plasma AVP concentrations were higher in the diabetic group compared with those in the normal group (p < 0.05). The NPY concentrations were higher in the normal subjects (p < 0.05) but no change in the mean level occurred in either group during hypoglycaemia. No group differences or changes in mean plasma concentrations were found for galanin, DSIP and CRH. These observations support the view that regulatory peptides, if involved in glucose homeostasis, may rather have a modulatory effect than a direct action in restoring normoglycaemia.
...
PMID:The response of regulatory peptides to moderate hypoglycaemia of short duration in type 1 (insulin-dependent) diabetes mellitus and in normal man. 128 60
It is well-known that diabetic patients develop peripheral and
autonomic neuropathy
, and recent review has also suggested the occurrence of central pathway abnormality in diabetics. In this article, we conducted the BAEP study on 61 cases of NIDDM and 11 cases of
IDDM
. Peak latency, interpeak latency (IPL) and peak amplitude of BAEPs were analyzed in each case. For further correlation, the motor and sensory nerve conduction velocities of median nerve, the blood sugar, the serum HbA1c were measured. Two nondiabetic groups, age and sex matched with NIDDM and
IDDM
groups, were used as control. In NIDDM group, the results showed prolongation of all peak latency and IPL except peak latency of wave II and wave IV in the left side and bilateral IPL III-V. There was no statistically significant amplitude difference between NIDDM and age-matched control group. The result of
IDDM
group revealed prolongation of all peak latency and IPL, except the right IPL III-V. As for amplitude, waves III and V in the right side and waves I and V in the left side were reduced as compared with the age-matched young control group. There was no statistically significant difference in all peak latencies and IPLs between NIDDM and
IDDM
groups. In both groups of NIDDM and
IDDM
, the MNCV and SNCV of median nerve were significantly delayed in conduction. The prolongation of III and V peak latency had a linear correlation with their amplitude reduction. In conclusion, both peripheral and central conduction dysfunction occur in both
IDDM
and NIDDM patients.
...
PMID:[Brainstem auditory evoked potentials in diabetes mellitus]. 131 48
Two patients, a 28-year-old male and a 70-year-old female, with chronic
insulin dependent diabetes mellitus
and evidence of
autonomic neuropathy
were studied using cortical evoked responses following esophageal balloon and electrical stimulation. Both patients had symptomatic gastroparesis, poor gastric emptying, and reduced gastroduodenal motility including abnormal results of scintigraphy and manometry. There was slowing of afferent vagal conduction but good evoked potential responses were recorded even though one patient could not feel electrical stimulation of either the proximal or distal esophagus. It is improbable that the gastric symptoms are due to an afferent
autonomic neuropathy
, but symptoms may well be related to impairment of motor vagal pathways. Nevertheless, afferent vagal pathways are involved in severe diabetes mellitus. The clinical significance of this delay in conduction velocity of afferent pathways remains to be established.
...
PMID:Evidence of impaired afferent vagal function in patients with diabetes gastroparesis. 138 75
Twenty six patients with
insulin dependent diabetes mellitus
underwent a gastric emptying test, a gall bladder contraction test, an orocaecal transit study, and a colon transit test. Eleven patients had signs of cardiovascular
autonomic neuropathy
, 15 patients were without signs of cardiovascular
autonomic neuropathy
. Mean gastric clearance of radioopaque markers ingested with a meal averaged 29.5 (2.3) markers per six hours in subjects without cardiovascular
autonomic neuropathy
compared with 17.8 (2.3) markers per six hours in patients with cardiovascular
autonomic neuropathy
(p < 0.02). Gall bladder emptying in response to graded CCK8 stimulation was impaired in five of 11 patients with cardiovascular
autonomic neuropathy
, whereas it was normal in the patients without cardiovascular
autonomic neuropathy
(p < 0.01). Oral caecal transit times were not significantly different in the two patient groups, whereas colonic transit was slower in the patients with cardiovascular
autonomic neuropathy
compared with the group without cardiovascular
autonomic neuropathy
(p < 0.02). There was no correlation between disturbed gastric clearance, impaired gall bladder contraction, and prolonged colonic transit time in the patients with cardiovascular
autonomic neuropathy
nor was there a correlation between any disturbed motor function and age or duration of diabetes. It is concluded that
autonomic neuropathy
can affect motor functions throughout the gastro-intestinal tract. Any disturbed motor function in the gut could therefore be one of the numerous expressions of diabetic neuropathy affecting the cardiovascular, the endocrine or the gastrointestinal system.
...
PMID:Non-invasive assessment of gastrointestinal motility disorders in diabetic patients with and without cardiovascular signs of autonomic neuropathy. 142 71
The fibrinolytic system was investigated in 38 patients (21 males and 17 females) affected by
type 1 diabetes
mellitus (18 free from complications, 10 with retinopathy, and 10 with
autonomic neuropathy
) and in 8 healthy controls. Two separate fibrinolysis-stimulating tests were done: standardized venous occlusion and 1-desamino-8-D-arginine vasopressin infusion. Plasma tissue plasminogen activator antigen and activity and plasma plasminogen activator inhibitor activity were measured. All the patients were in good metabolic control (mean HbA1c 7.4%, range 6.1-8.0%). No significant differences were observed either between the diabetic patients and the control subjects, nor among the subgroups of diabetic patients. The fibrinolytic system is probably not involved in
type 1 diabetes
mellitus.
...
PMID:Normal tissue plasminogen activator and plasminogen activator inhibitor activity in plasma from patients with type 1 diabetes mellitus. 145 17
34
IDDM
patients (17 hypertensive, 17 normotensive) were studied by using a noninvasive cardiovascular autonomic function test. The total average incidence of abnormal autonomic function test results was 31.7%. The average incidence of abnormal parasympathetic autonomic function test results was 40.5%, and that of abnormal sympathetic function test results was 22.9%. No significant difference (P greater than 0.05) appeared between the hypertensive and normotensive groups. This study suggests that the cardiovascular autonomic function test is useful in diagnosing
autonomic neuropathy
in
IDDM
patients.
...
PMID:[Cardiovascular effects in diabetic autonomic neuropathy]. 153 59
Although neuropathy has long been recognized as a complication of diabetes, the impact of this condition has not been adequately established. The prevalence of diabetic neuropathy is virtually unknown because the published studies differ considerably with regard to definition, method of assessment, and patient selection. Furthermore, the determination of prevalence has been hampered by the fact that there is no generally accepted classification of the variety of manifestations of diabetic neuropathy. The introduction of new sensitive diagnostic methods aids in the detection of less severe stages of neuropathy, as compared with clinically based assessment, and renders the disease more prevalent. The prevalence of diabetic neuropathy in the few reported population-based studies was approximately 30%. We have evaluated the prevalence of cardiovascular
autonomic neuropathy
in a group of approximately 1000 diabetic patients randomly included from 21 hospitals in Germany, Austria, and Switzerland. The results of this study and those of a prospective study on the natural history of neural dysfunction during the first 5 years after diagnosis of
type 1 diabetes
will be presented.
...
PMID:The epidemiology of diabetic neuropathy. Diabetic Cardiovascular Autonomic Neuropathy Multicenter Study Group. 156 59
Recent reports have suggested that xamoterol, a beta 1 adrenoceptor partial agonist with 43% intrinsic sympathomimetic activity improves symptomatic postural hypotension in patients with primary autonomic failure. To evaluate the use of xamoterol in eleven insulin dependent patients with diabetes mellitus who had postural hypotension (over 20 mmHg systolic blood pressure) secondary to
autonomic neuropathy
, we performed a double-blind, randomized, placebo controlled crossover study with xamoterol (200 mg bd orally) for 1 month. Treatment with xamoterol raised supine systolic blood pressure by 11 mmHg but a reduced standing systolic blood pressure by 11 mmHg with an increase in the standing-supine systolic blood pressure difference. No significant differences were observed in symptom score, HbA1 or plasma glucose. We conclude that oral xamoterol raises supine systolic blood pressure but paradoxically lowers standing systolic blood pressure further in
insulin dependent diabetes mellitus
. Xamoterol is unlikely to be of value in the management of postural hypotension in diabetic patients with
autonomic neuropathy
.
...
PMID:A double-blind crossover study of oral xamoterol in postural hypotension due to diabetic autonomic neuropathy. 168 39
Sixty patients with
type I diabetes mellitus
underwent an ergometric stress test (EST) to evaluate the relationship between cardiac
autonomic neuropathy
(CAN) and hemodynamic changes during EST. All patients were divided into 2 groups: in the Group A were included 26 patients (mean age 43 +/- 9 years) with impairment of 2 or more autonomic tests according to Ewing (patients with CAN) and in the Group B were included 34 patients (mean age 38 +/- 13 years) without CAN. The EST was symptom-limited and performed with load increases of 25 W every 3 min. No positive EST were observed in both groups. Heart rate (HR) at rest and systolic blood pressure (SBP) at maximum common workload were significantly higher in Group A than in Group B. Moreover, a significant linear correlation was found between a CAN score and SBP x HR product at rest and at maximal workload. These findings are correlated with increased sympathetic activity due to a parasympathetic impairment. The data show the relationship between hemodynamic changes during EST and the Ewing test used in the diagnosis of CAN.
...
PMID:[Cardiovascular adaptation during cycloergometric exercise test in insulin-dependent diabetics with or without autonomic cardiopathy]. 179 97
We report on the results of a study on the peripheral nerve function in 40 patients with
type I diabetes mellitus
with onset in pediatric age. Results have shown a significant decrease in motor and sensory nerve conduction velocities (NCV) in a high percentage of cases, correlated with the degree of metabolic control. The finding of NCV slowing also in patients with a history of diabetes of less than 10 years and the presence in these cases of a high number of complications (
autonomic neuropathy
, nephropathy, retinopathy) may suggest that peripheral neuropathy is an early-onset complication and that its prompt recognition through neurophysiological investigations can have some predictive value in forecasting other complications. This hypothesis is to be verified through prospective studies.
...
PMID:[Peripheral neuropathy in infantile and juvenile diabetes. A neurophysiological study]. 194 99
1
2
3
4
5
6
7
8
9
10
Next >>